
    
      Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to
      measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The
      LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic
      dehydrogenase release from lysed cells.
    
  